| DESCRIPTION | - Cancer, (20060000), vol. 107, pages 2866 - 2872 |
| DESCRIPTION | - Cancer Res., (19990701), vol. 59, no. 13, pages 3128 - 33 |
| DESCRIPTION | - Cancer Res., (20100000), vol. 70, no. 7, pages 2665 - 74 |
| DESCRIPTION | - Cell, (20150000), vol. 160, pages 48 - 61 |
| DESCRIPTION | - Cell. Mol. Immunol., (20110000), vol. 8, pages 59 - 66 |
| DESCRIPTION | - CHEMICAL ABSTRACTS, Database accession no. 7365-45-9 |
| DESCRIPTION | - CHIRGWIN, J.M. et al., Biochemistry, (19790000), vol. 18, pages 5294 - 5299 |
| DESCRIPTION | - Clinical Cancer Research, (20040000), vol. 10, pages 1274 - 1281 |
| DESCRIPTION | - Eur. J. Cancer, (20080000), vol. 44, pages 1875 - 1882 |
| DESCRIPTION | - Eur. J. Immunol., (20100000), vol. 40, pages 3325 - 3335 |
| DESCRIPTION | - Expert Opinion on Therapeutic Patents, (19960000), vol. 6, no. 5, pages 441 - 456 |
| DESCRIPTION | - FROHMAN, M.A. et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, page 8998 |
| DESCRIPTION | - J. Biol. Chem., (19970000), vol. 272, no. 28, pages 17251 - 4 |
| DESCRIPTION | - J. Clin. Oncol., (20060000), vol. 24, pages 5373 - 5380 |
| DESCRIPTION | - J. Clin. Oncol., (20070000), vol. 25, pages 2586 - 2593 |
| DESCRIPTION | - J. Immunol., (19960000), vol. 157, no. 7, pages 2759 - 63 |
| DESCRIPTION | - KOHLERMILSTEIN, Nature, (19750000), vol. 256, pages 495 - 497 |
| DESCRIPTION | - Nat. Med., (20040000), vol. 10, pages 942 - 949 |
| DESCRIPTION | - Nat. Rev. Immunol., (20060000), vol. 6, no. 4, pages 295 - 307 |
| DESCRIPTION | - Nature Biotechnology, (20050000), vol. 23, page 1105 |
| EXAMINATION | - ONIZUKA S ET AL, "Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (19990701), vol. 59, no. 13, ISSN 0008-5472, pages 3128 - 3133, XP002255931 |
| OPPOSITION | - Ali Tahir Syed M., Et Al, "Loss of IFN-y Production by Invariant NK T Cells in Advanced Cancer", The Journal of Immunology, (20010101), vol. 167, pages 4046 - 4050, XP055866405 |
| OPPOSITION | - Anonnmous, "PE anti-mouse CD279(PD-1)ANTIBODY", Biolegend, (20160217), Biolegend, (20201014), XP055739741 |
| OPPOSITION | - Anonymous, "Antibody Isotype Families", InvivoGen, (20160604), InvivoGen, URL: http://www.invivogen.com/antibody-isotypes, (20211216), XP055873608 |
| OPPOSITION | - Anonymous, "BV421 Mouse Anti-Human CCR8 (CD 198)", BD Biosciences, (20160101), pages 1 - 2, BD Biosciences, (20210126), XP055769025 |
| OPPOSITION | - Anonymous, "CHEMOKINE, CC MOTIF, RECEPTOR 4; CCR4", Waybackmachine, (20170313), page 1, XP055868962 |
| OPPOSITION | - Anonymous, "Human/Rat CCR8 PE-conjugated Antibody Monoclonal Rat IgG2B Clone # 191704 Catalog Number: FAB1429P", rndsystems.com, pages 1 - 1, rndsystems.com, URL: https://resources.rndsystems.com/pdfs/datasheets/fab1429p.pdf?v=20210614&_ga=2.136989685.418594252.1623694178-574244234.1606922094&_gac=1.140764550.1623749608.EAIaIQobChMIssnGlaqZ8QIVE9ayCh3jEQmrEAAYAiAAEgLaf_D_BwE, (20210615), XP055813916 |
| OPPOSITION | - Anonymous, "IgG antibody effector activities and affinities", Review InvivoGen, (20110101), Review InvivoGen, (20211216), XP055873597 |
| OPPOSITION | - Anonymous, "Immunoglobulin G", Review Invivogen, (20110101), pages 1 - 1, Review Invivogen, URL: https://www.invivogen.com/sites/default/files/invivogen/resources/documents/reviews/review-ImmunoglobulinG-invivogen.pdf, (20220113), XP055878611 |
| OPPOSITION | - Anonymous, "Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer.", ClinicalTrials.gov, (20160217), pages 1 - 7, ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/show/NCT01929486, (20220113), XP055878667 |
| OPPOSITION | - Anonymous, "Purified anti-human CD 198 (CCR8) Antibody clone L263G8", Biolegend, (20131009), pages 1 - 3, XP055878589 |
| OPPOSITION | - Anonymous, "Purified anti-mouse CD 198 (CCR8) Antibody", Biolegend Enabling Legendary Discovery, (20151216), pages 1 - 2, Biolegend Enabling Legendary Discovery, (20210126), XP055769023 |
| OPPOSITION | - Anonymous, "Purified anti-mouse CD198 (CCR8) Antibody", Biolegend - Product sheet, (20151216), pages 1 - 2, Biolegend - Product sheet, URL: https://www.biolegend.com/en-us/products/purified-anti-mouse-cd198-ccr8-antibody-12025, (20210126), XP055768629 |
| OPPOSITION | - Anonymous, "Side effects of cancer treatment", Mcmillan - Fact Sheet, (20130101), pages 1 - 7, Mcmillan - Fact Sheet, URL: https://cdn.macmillan.org.uk, (20211216), XP055873612 |
| OPPOSITION | - Anonymous, "Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO- 4538/BMS-936558) in Subjects With Advanced Solid Tumors", ClinicalTrials.gov, (20190611), ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/show/NCT02476123, (20211216), XP055873606 |
| OPPOSITION | - Anonymous, "Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors", clinicalTrials.gov, (20170121), URL: https://clinicaltrials.gov/ct2/show/results/NCT02301130?view=results, XP055871986 |
| OPPOSITION | - Anonymous, "Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab +Tremelimumab in Subjects w/ Advanced Solid Tumors", clinicaltrials.gov, (20180501), clinicaltrials.gov, URL: https://clinicaltrials.gov/ct2/show/NCT02301130, (20211216), XP055873604 |
| OPPOSITION | - Anonymous, "Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors NCT02301130", ClinicalTrials.gov NCT02301130, (20170121), pages 1 - 7, ClinicalTrials.gov NCT02301130, URL: https://clinicaltrials.gov/ct2/show/NCT02301130, (20220113), XP055878782 |
| OPPOSITION | - Anonymous, "Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors", clinicalTrials.gov, (20170122), clinicalTrials.gov, (20211216), XP055873652 |
| OPPOSITION | - Anonymous, "Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors NCT02705105", ClinicalTrials.gov NCT02705105, (20170119), pages 1 - 10, ClinicalTrials.gov NCT02705105, URL: https://clinicaltrials.gov/ct2/show/NCT02705105, (20220113), XP055878779 |
| OPPOSITION | - Anonymous, "Technical Data Sheet BV421 Mouse Anti-Human CCR8 (CD198)", bdbiosciences.com, (2016), pages 1 - 2, bdbiosciences.com, URL: https://www.bdbiosciences.com/content/bdb/paths/generate-tds-document.us.566379.pdf, (20210615), XP055813996 |
| OPPOSITION | - Anonymous, "Technical Manual: mFcgammaRIV ADCC Reporter Bioassay, Core Kit", Promega, (20170101), pages 1 - 20, Promega, (20210126), XP055769013 |
| OPPOSITION | - BD Horizon™, "BV421 Mouse Anti-Human CCR8 (CD198)", Technical Data Sheet, (2016), XP055813996 |
| OPPOSITION | - DAS et al., "Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses", J Exp Med, (20130000), vol. 210, no. 8, pages 1509 - 1528, XP055768993 |
| OPPOSITION | - DAS et al., "Tumor cell entry into the lymph node is controlled by CCL 1 chemokine expressed by lymph node lymphatic sinuses", J. Exp. Med., (20130722), vol. 210, no. 8, page 1509, XP055768993 |
| OPPOSITION | - DAS et al., "Tumor cell entry into the lymph node is controlled by CCL 1 chemokine expressed by lymph node lymphatic sinuses", Journal of Experimental Medicine, (20130700), vol. 210, no. 8, pages 1509 - 1528, XP055768993 |
| OPPOSITION | - DAS S et al., "Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses", J Exp Med., (20130722), vol. 210, no. 8, pages 1509 - 28, XP055768993 |
| OPPOSITION | - Debes et al., "CCL8 and skin T cells - an allergic 2011 attraction", Nature immunology, (20110201), vol. 12, no. 2, pages 111 - 112, XP055768623 |
| OPPOSITION | - DEBES et al., "CCL8 and skin T cells - an allergic attraction", Nat. Immunol., (20110000), vol. 1 2, no. 2, pages 111 - 112, XP055768623 |
| OPPOSITION | - EMA, "Herceptin 150 mg powder for concentrate for solution for infusion", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, (20190705), pages 1 - 92, URL: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf, XP055873633 |
| OPPOSITION | - EMA, "MabThera 100 mg concentrate for solution for infusion", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, (2019), pages 1 - 152, URL: https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf, XP055873618 |
| OPPOSITION | - Fda, "KEYTRUDA® (pembrolizumab) for injection, for intravenous use", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20161001), pages 1 - 26, HIGHLIGHTS OF PRESCRIBING INFORMATION, (20240121), XP093121873 |
| OPPOSITION | - Fda, "POTELIGEO (mogamulizumab-kpkc)", CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761051Orig1s000. MULTI-DISCIPLINE REVIEW, (20180808), CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761051Orig1s000. MULTI-DISCIPLINE REVIEW, URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761051Orig1s000MultidisciplineR.pdf, (20240121), XP093121871 |
| OPPOSITION | - Fda, "TECENTRIQ® (atezolizumab) injection, for intravenous use", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20161001), pages 1 - 23, HIGHLIGHTS OF PRESCRIBING INFORMATION, (20240121), XP093121875 |
| OPPOSITION | - Fda, "YERVOY (ipilimumab) injection, for intravenous use", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20151001), pages 1 - 32, HIGHLIGHTS OF PRESCRIBING INFORMATION, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf, (20240121), XP093121872 |
| OPPOSITION | - GANGULY et al., "The role of dendritic cells in autoimmunity", Nat Rev Immunol, (20130000), vol. 13, no. 8, pages 566 - 577, XP055868977 |
| OPPOSITION | - GUPTA et al., "Antibodies against G-protein coupled receptors: novel uses in screening and drug development", Comb Chem High Throughput Screen., (20080000), vol. 11, no. 6, pages 463 - 467, XP055868956 |
| OPPOSITION | - Hideya Onishi, Takashi Morisaki, Mitsuo Katano, "Immunotherapy Approaches Targeting Regulatory T-Cells", ANTICANCER RESEARCH, (20120301), pages 997 - 1004, XP055559091 |
| OPPOSITION | - "Immunoglobulin G", InvivoGen - Review, (20110101), XP055768630 |
| OPPOSITION | - James M. Coghill et al, "CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease", Blood, (20130801), vol. 122, no. 5, pages 825 - 836, XP055768611 |
| OPPOSITION | - Jim Stallard, "New Approach Could Boost Immunotherapy for Breast Cancer", Memorial Sloan Kettering Cancer Center, (20161129), pages 1 - 5, Memorial Sloan Kettering Cancer Center, (20210126), XP055768936 |
| OPPOSITION | - Jim Stallard, "New Approach Could Boost Immunotherapy for Breast Cancer", Memorial Sloan Kettering Cancer Center, (20161129), pages 1 - 5, Memorial Sloan Kettering Cancer Center, URL: https://www.mskcc.org/news/new-approach-could-boost-immunotherapy-for-breast-cancer, (20210126), XP055768936 |
| OPPOSITION | - Jo Van Ginderachter et al, "Blockade of the CCR8 chemokine receptor as novel cancer therapy", VUB Project information, (20170101), VUB Project information, URL: https://cris.vub.be/en/projects/blockade-of-the-ccr8-chemokine-receptor-as-novel-cancer-therapy(0869ab0e-ebdf-4039-9236-5082675cdc15).html, (20210126), XP055768612 |
| OPPOSITION | - KIPPS et al., "Importance of Immunoglobulin Isotype in Human Antibody-Dependent, Cell -Mediated Cytotoxicity Directed by Murine Monoclonal Antibodies", J. Exp. Med., (19850101), vol. 161, page 1, XP002609364 |
| OPPOSITION | - ONISHI H et al., "Immunotherapy approaches targeting regulatory T-cells", Anticancer Res, (20120300), vol. 32, no. 3, pages 997 - 1003, XP055559091 |
| OPPOSITION | - ONIZUKA S et al., "Tumor rejection by in vivo administration of anti- CD 25 (interleukin-2 receptor alpha) monoclonal antibody", Cancer Res., (19990701), vol. 59, no. 13, pages 3128 - 33, XP002255931 |
| OPPOSITION | - ONIZUKA S, ET AL, "Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.", Cancer research, American Association for Cancer Research, US, US , (19990701), vol. 59, no. 13, ISSN 0008-5472, pages 3128 - 3133, XP002255931 |
| OPPOSITION | - Penaloza-Macmaster Pablo, Et Al, "Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection", The Journal of Experimental Medicine, (20140101), vol. 211, no. 9, pages 1905 - 1918, XP055866408 |
| OPPOSITION | - PERNAMBUCO-HOLSTEN C., "Immunotherapy Combination Nivolumab Plus Ipilimumab Receives FDA Approval for Metastatic Melanoma", MSKCC, (20151001), pages 1 - 4, XP055868997 |
| OPPOSITION | - Promega, "mFcyR ADCC Reporter Bioassaym", Promega - Technical Manual, (20170101), pages 1 - 20, Promega - Technical Manual , URL: https://www.promega.com/-/media/files/resources/protocols/technical-manuals/101/mfcgammmariv-adcc-reporter-bioassay-core-kit.pdf?rev=7a6eb26629444e4584399408b9a2b828&sc_lang=en, (20211216), XP055873594 |
| OPPOSITION | - "Purified anti-mouse CD198 (CCR8) Antibody", Biolegend - Product sheet, (20151216), XP055768629 |
| OPPOSITION | - Pyszniak Maria, Et Al, "Percentages of NKT cells in the tissues of patients with non-small cell lung cancer who underwent surgical treatment", Kardiochirurgia i Torakochirurgia Polska, (20140101), vol. 11, no. 1, pages 34 - 39, XP055866402 |
| OPPOSITION | - SLAUENWHITE et al., "Regulation of NKT cell localization in homeostasis and infection", Front Immunol, (20150000), vol. 6, no. 255, pages 1 - 19, XP055868973 |
| OPPOSITION | - STALLARD, "FDA Approves 'Game Changer' Immunotherapy Drug for Bladder Cancer", MSKCC, (20160518), pages 1 - 11, URL: https://www.mskcc.org/news/fda- approves-game-changer-immunotherapy-drug-bladder, XP055869007 |
| OPPOSITION | - STALLARD, "New Approach Could Boost Immunotherapy for Breast Cancer", Memorial Sloan Kettering Cancer Center, (20161129), pages 1 - 5, XP055768936 |
| OPPOSITION | - Tanaka Atsushi; Sakaguchi Shimon, "Regulatory T cells in cancer immunotherapy", Cell Research, (20170000), vol. 27, pages 109 - 118, XP055866424 |
| OPPOSITION | - Tanaka Atsushi, Sakaguchi Shimon, "Regulatory T cells in cancer immunotherapy", Cell Research, (20170101), vol. 27, pages 109 - 118, XP055866424 |
| OPPOSITION | - TANAKA et al., "Regulatory T cells in cancer immunotherapy", Cell Research, (20161220), vol. 27, pages 109 - 118, XP055866424 |
| OPPOSITION | - Tecentriq label |
| OPPOSITION | - T. J. KIPPS ET AL., "Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies.", Journal of Experimental Medicine, Rockefeller University Press, US, US , (19850101), vol. 161, no. 1, ISSN 0022-1007, pages 1 - 17, XP002609364 |
| OPPOSITION | - TONTONOZ, "Combination Immunotherapy Shows New Promise for Lung Cancer", MSKCC, (20160601), pages 1 - 12, XP055869000 |
| OPPOSITION | - TONTONOZ, "Immunotherapy Pioneered at MSK Receives FDA Approval for Advanced Kidney Cancer", MSKCC, (20151204), pages 1 - 9, XP055869004 |
| OPPOSITION | - Whiteside, Et Al, "CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function", Immunology, (20210101), vol. 163, pages 512 - 520, XP055866395 |
| OPPOSITION | - Wilcox Ryan A, "Mogamulizumab: 2 birds, 1 stone", Blood, (20150000), vol. 125, no. 12, pages 1847 - 1848, XP055866757 |
| OPPOSITION | - Yamamoto, K et al, "Developmental Therapeutics", ESMO, (20170901), vol. 28, no. 5, page 611, XP055739768 |
| OPPOSITION | - Li Xingrui; Kostareli Efterpi; Suffner Janine; Garbi Natalio; Hämmerling Günter J, "Efficient Treg depletion induces T-cell infiltration and rejection of large tumors", Eur J Immunol., (20100000), vol. 40, no. 12, pages 3325 - 3335, XP055844150 |
| OPPOSITION | - Jamila Louahed et al, "CCR8‐dependent activation of the RAS/MAPK pathway mediates anti‐apoptotic activity of I‐309/CCL1 and vMIP‐I", European Journal of Immunology, Wiley-VCH, Hoboken, USA, Hoboken, USA, (20030131), vol. 33, no. 2, doi:10.1002/immu.200310025, ISSN 0014-2980, pages 494 - 501, XP071221568 |
| OPPOSITION | - Wei Peng; Ting Han; Wen-Bo Xin; Xiao-Gang Zhang; Qiao-Yan Zhang; Min Jia; Lu-Ping Qin, "Comparative research of chemical constituents and bioactivities between petroleum ether extracts of the aerial part and the rhizome of Atractylodes macrocephala", N Am J Med Sci., (20100000), vol. 3, no. 3, pages 146 - 151, XP019881300 |
| OPPOSITION | - TAN et al., "Crystal clear: visualizing the intervention mechanism of the PD- 1/PD-L 1 interaction by two cancer therapeutic monoclonal antibodies", Protein & Cell, (20161007), vol. 7, no. 12, doi:10.1007/s13238-016-0337-7, pages 866 - 877, XP036124172 |
| OPPOSITION | - TAN et al., "Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L 7 interaction by two cancer therapeutic - monoclonal antibodies", Protein Cell, (20160000), vol. 7, no. 12, doi:10.1007/s13238-016-0337-7, pages 866 - 877, XP036124172 |
| OPPOSITION | - Tan Shuguang; Chen Danqing; Liu Kefang; He Mengnan; Song Hao; Shi Yi; Liu Jun; Zhang Catherine W-H; Qi Jianxun; Yan Jinghua; Gao Shan; Gao George F, "Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies", Protein & cell, (20160000), vol. 7, no. 12, pages 866 - 877, XP036124172 |
| OPPOSITION | - Tan Shuguang; Chen Danqing; Liu Kefang; He Mengnan; Song Hao; Shi Yi; Liu Jun; Zhang Catherine W.-H.; Qi Jianxun; Yan Jinghua; Gao Shan; Gao George F., "Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies", Protein & cell, Springer Asia, Beijing, CN, Beijing, CN , (20161104), vol. 7, no. 12, doi:10.1007/s13238-016-0337-7, ISSN 1674-800X, pages 866 - 877, XP036124172 |
| OPPOSITION | - Tan Shuguang et al, "Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies", Protein & cell, Springer Asia, Beijing, CN, Beijing, CN , (20161104), vol. 7, no. 12, doi:10.1007/s13238-016-0337-7, ISSN 1674-800X, pages 866 - 877, XP036124172 |
| OPPOSITION | - DAY CP et al., "Preclinical mouse cancer models: a maze of opportunities and challenges", Cell, (20150924), vol. 163, no. 1, doi:10.1016/j.cell.2015.08.068, pages 39 - 53, XP029280472 |
| OPPOSITION | - DAY et al., "Preclinical mouse cancer models: a 2015 maze of opportunities and challenges", Cell, (20150000), vol. 163, doi:10.1016/j.cell.2015.08.068, pages 39 - 53, XP029280472 |
| OPPOSITION | - TOPALIAN et al., "Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity", Curr Opin Immunol., (20120109), vol. 24, no. 2, doi:10.1016/j.coi.2011.12.009, pages 207 - 12, XP002714810 |
| OPPOSITION | - SPAIN et al., "Management of toxicities of 2016 immune checkpoint inhibitors", Cane. Treat. Rev., (20160000), vol. 44, doi:10.1016/j.ctrv.2016.02.001, pages 51 - 60, XP029434607 |
| OPPOSITION | - Spain et al., "Management of toxicities of immune checkpoint inhibitors", Cancer Treatment Reviews, AMSTERDAM, NL , (20160206), vol. 44, doi:10.1016/j.ctrv.2016.02.001, ISSN 0305-7372, pages 51 - 60, XP029434607 |
| OPPOSITION | - Spain Lavinia; Diem Stefan; Larkin James, "Management of toxicities of immune checkpoint inhibitors", Cancer Treatment Reviews, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20160206), vol. 44, doi:10.1016/j.ctrv.2016.02.001, ISSN 0305-7372, pages 51 - 60, XP029434607 |
| OPPOSITION | - KLARENBEEKA et al., "Targeting chemokines and chemokine receptors with antibodies", Drug Discov Today Technol, (20120000), vol. 9, no. 4, doi:10.1016/j.ddtec.2012.05.003, pages e227 - 314, XP055435390 |
| OPPOSITION | - KLARENBEEK et al., "Targeting chemokines and chemokine receptors with antibodies", Drug Discovery Today: Technologies, (20121200), vol. 9, no. 4, doi:10.1016/j.ddtec.2012.05.003, pages e237 - e244, XP055435390 |
| OPPOSITION | - DEMPKE WCM et al., "Second- and third- generation drugs for immuno-oncology treatment-The more the better?", Eur J Cancer, (20170210), vol. 74, doi:10.1016/j.ejca.2017.01.001, pages 55 - 72, XP029933747 |
| OPPOSITION | - Dempke Wolfram C.M et al, "Second- and third-generation drugs for immuno-oncology treatment—The more the better?", European Journal of Cancer, Elsevier, Amsterdam NL, Amsterdam NL , (20170210), vol. 74, doi:10.1016/j.ejca.2017.01.001, ISSN 0959-8049, pages 55 - 72, XP029933747 |
| OPPOSITION | - DE SIMONE et al., Immunity, (20160000), vol. 45, pages 1135 - 1147, XP029809250 |
| OPPOSITION | - DE SIMONE et al., "Transcriptional landscape of 2016 human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells", Imm u nity, (20160000), vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.021, pages 1135 - 1147, XP029809250 |
| OPPOSITION | - DE SIMONE et al., "Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells", Immunity, (20161115), vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.021, page 1135, XP029809250 |
| OPPOSITION | - DE SIMONE et al., "Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells", Immunity, (20161115), vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.021, pages 1135 - 1147, XP029809250 |
| OPPOSITION | - De Simone et al., "Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells", Immunity, AMSTERDAM, NL , (20161115), vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.021, ISSN 1074-7613, pages 1135 - 1147, XP029809250 |
| OPPOSITION | - De Simone Marco; Arrigoni Alberto; Rossetti Grazisa; Gruarin Paola; Ranzani Valeria; Politano Claudia; Bonnal Raoul J P; Provasi Elena; Sarnicola Maria Lucia; Panzeri Ilaria; Moro Monica; Crosti Mariacristina; Mazzara Saveria; Vaira Valentina; Bosari Silvano; Palleschi Alessandro; Santambrogio Luigi; Bovo Giorgio; Zucchini Nicola; Totis Mauro; Gianotti Luca; Cesana Giancarlo; Perego Roberto A; Maroni Nirvana; Pisani Ceretti Andrea; Opocher Enrico; De Francesco Raffaele; Geginat Jens; Stunnenberg Hendrik G; Abrignani Sergio; Pagani Massimiliano, "Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells", Immunity, (20160000), vol. 45, no. 5, pages 1135 - 1147, XP029809250 |
| OPPOSITION | - De Simone Marco; Arrigoni Alberto; Rossetti Grazisa; Gruarin Paola; Ranzani Valeria; Politano Claudia; Bonnal Raoul J.P.; Provasi Elena; Sarnicola Maria Lucia; Panzeri Ilaria; Moro Monica; Crosti Mariacristina; Mazzara Saveria; Vaira Valentina; Bosari Silvano; Palleschi Alessandro; Santambrogio Luigi; Bovo Giorgio; Zucchini Nicola; Totis Mauro; Gianotti Luca; Cesana Giancarlo; Perego Roberto A.; Maroni Nirvana; Pisani Ceretti Andrea; Opocher Enrico; De Francesco Raffaele; Geginat Jens; Stunnenberg Hendrik G.; Abrignani Sergio; Pagani Massimiliano, "Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells", Immunity, Cell Press, AMSTERDAM, NL , (20161115), vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.021, ISSN 1074-7613, pages 1135 - 1147, XP029809250 |
| OPPOSITION | - DE SIMONE M et al., "Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor- Infiltrating T Regulatory Cells", Immunity, vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.021, pages 1135 - 1147, XP029809250 |
| OPPOSITION | - Simone De Marco et al, "Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL , (20161115), vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.021, ISSN 1074-7613, pages 1135 - 1147, XP029809250 |
| OPPOSITION | - Simone Marco et al, "Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL , (20161115), vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.021, ISSN 1074-7613, pages 1135 - 1147, XP029809250 |
| OPPOSITION | - PLITAS et al., Immunity, (20160000), vol. 45, no. 5, pages 1122 - 1134, XP029809259 |
| OPPOSITION | - PLITAS et al., "Regulatory T cells exhibit distinct 2016 features in human breast cancer", Immunity, (20160000), vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.032, pages 1122 - 1134, XP029809259 |
| OPPOSITION | - PLITAS et al., "Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer", Immunity, (20161115), vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.032, page 1122, XP029809259 |
| OPPOSITION | - PLITAS et al., "Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer", Immunity, (20161115), vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.032, pages 1122 - 1134, XP029809259 |
| OPPOSITION | - Plitas et al., "Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer", Immunity, AMSTERDAM, NL , (20161115), vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.032, ISSN 1074-7613, pages 1122 - 1134, XP029809259 |
| OPPOSITION | - Plitas George et al, "Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL , (20161115), vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.032, ISSN 1074-7613, pages 1122 - 1134, XP029809259 |
| OPPOSITION | - Plitas George; Konopacki Catherine; Wu Kenmin; Bos Paula D; Morrow Monica; Putintseva Ekaterina V; Chudakov Dmitriy M; Rudensky Alexander Y, "Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer", Immunity, (20160000), vol. 45, no. 5, pages 1122 - 1134, XP029809259 |
| OPPOSITION | - Plitas George; Konopacki Catherine; Wu Kenmin; Bos Paula D.; Morrow Monica; Putintseva Ekaterina V.; Chudakov Dmitriy M.; Rudensky Alexander Y., "Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer", Immunity, Cell Press, AMSTERDAM, NL , (20161115), vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.032, ISSN 1074-7613, pages 1122 - 1134, XP029809259 |
| OPPOSITION | - PLITAS G et al., "Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer", Immunity, (20161115), vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.032, pages 1122 - 1134, XP029809259 |
| OPPOSITION | - ARCE VARGAS F et al., "Fc-Optimized Anti- CD 25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors", Immunity, (20170411), vol. 46, no. 4, doi:10.1016/j.immuni.2017.03.013, pages 577 - 586, XP055487134 |
| OPPOSITION | - Frederick Arce Vargas et al, "Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors", Immunity, Cell Press, AMSTERDAM, NL , (20170401), vol. 46, no. 4, doi:10.1016/j.immuni.2017.03.013, ISSN 1074-7613, pages 577 - 586, XP055487134 |
| OPPOSITION | - Frederick Arce Vargas et al, "Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL , (20170401), vol. 46, no. 4, doi:10.1016/j.immuni.2017.03.013, ISSN 1074-7613, pages 577 - 586, XP055487134 |
| OPPOSITION | - VARGAS et al., "Fc-Optimized Anti- CD 25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors", Immunity, (20170411), vol. 46, doi:10.1016/j.immuni.2017.03.013, page 577, XP055487134 |
| OPPOSITION | - Vargas Frederick Arce et al, "Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL , (20170401), vol. 46, no. 4, doi:10.1016/j.immuni.2017.03.013, ISSN 1074-7613, pages 577 - 586, XP055487134 |
| OPPOSITION | - Ali; O'Boyle S; Mellor G; Kirby P; J A, "An apparent paradox: Chemokine receptor agonists can be used for anti-inflammatory therapy", Mol Immunol., (20061126), vol. 44, no. 7, pages 1477 - 1482, XP005780827 |
| OPPOSITION | - IRANI et al., "Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases", Molecular Immunology, (20150418), vol. 67, doi:10.1016/j.molimm.2015.03.255, pages 171 - 182, XP029246901 |
| OPPOSITION | - IRANI et al., "Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases", Mol. Immunol., (20150418), vol. 67, doi:10.1016/j.molimm.2015.03.255, page 171, XP029246901 |
| OPPOSITION | - Redman J.M.; Hill E.M.; AlDeghaither D.; Weiner L.M., "Mechanisms of action of therapeutic antibodies for cancer", MOLECULAR IMMUNOLOGY, GB , (20150423), vol. 67, no. 2, doi:10.1016/j.molimm.2015.04.002, ISSN 0161-5890, pages 28 - 45, XP029246903 |
| OPPOSITION | - Chiu Mark L; Gilliland Gary L, "Engineering antibody therapeutics", Current Opinion in Structural Biology, GB , (20160812), vol. 38, doi:10.1016/j.sbi.2016.07.012, ISSN 0959-440X, pages 163 - 173, XP029707735 |
| OPPOSITION | - SHUPTRINE et al., "Monoclonal Antibodies for the Treatment of Cancer", Semin. Cancer Biol., (20120108), vol. 22, no. 1, doi:10.1016/j.semcancer.2011.12.009, page 3, XP028459114 |
| OPPOSITION | - ANDREW M SCOTT et al., "Antibody therapy of cancer", Nat Rev Cancer, (20120322), vol. 12, no. 4, pages 278 - 287, XP055023837 |
| OPPOSITION | - L. Shipman, "Interrogating intratumoral Treg cells.", NATURE REV. IMMUNOL, (20161205), vol. 17, doi:10.1038/nri.2016.137, pages 4 - 5, XP055739876 |
| OPPOSITION | - SHIPMAN et al., "Interrogating intratumoral Treg cells", Nature Rev. Immunol., (20161205), vol. 17, doi:10.1038/nri.2016.137, page 4, XP055739876 |
| OPPOSITION | - Shipman L, "Interrogating intratumoral Treg cells", Nat Rev Immunol, (20160000), vol. 17, pages 4 - 5, XP055739876 |
| OPPOSITION | - CHAN ANDREW C , CARTER PAUL J, "Therapeutic antibodies for autoimmunity and inflammation", Nature Reviews Immunology, Nature Publishing Group UK, London, London, (20100501), vol. 10, no. 5, doi:10.1038/NRI2761, ISSN 1474-1733, pages 301 - 316, XP002665072 |
| OPPOSITION | - Rosenberg Helene F; Dyer Kimberly D; Foster Paul S, "Eosinophils: changing perspectives in health and disease", Nature Reviews Immunology, (20130000), vol. 13, no. 1, pages 9 - 22, XP037065594 |
| OPPOSITION | - CHIARION-SILENI V et al., "Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma", N Engl J Med, (20150531), vol. 373, no. 1, doi:10.1056/NEJMoa1504030, pages 23 - 34, XP055553658 |
| OPPOSITION | - James Larkin et al, "Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma", The New England journal of medicine, Massachusetts Medical Society, US, US , (20150702), vol. 373, no. 1, doi:10.1056/NEJMoa1504030, ISSN 0028-4793, pages 23 - 34, XP055316141 |
| OPPOSITION | - Cats Peter; Kuipers Sander; de Wind Sacha; van Damme Robin; Coli Gabriele M; Dijkstra Marjolein; van Roij René, "Machine-learning free-energy functionals using density profiles from simulations", J Immunother Cancer, (20210319), vol. 9, no. 3, pages 1 - 11, XP012254919 |
| OPPOSITION | - DIETZE et al., "Transient depletion of regulatory T 2011 cells in transgenic mice reactivates virus-specific CD 8+ T cells andreduces chronic retroviral set points", PNAS, (20110000), vol. 108, no. 6, doi:10.1073/pnas.1015148108, pages 2420 - 2425, XP055768620 |
| OPPOSITION | - Dietze et al., "Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD8+ T cells and reduces chronic retroviral set points", Proceedings of the National Academy of Sciences, (20110208), vol. 108, no. 6, doi:10.1073/pnas.1015148108, ISSN 0027-8424, pages 2420 - 2425, XP055768620 |
| OPPOSITION | - DIETZE KK et al., "Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD 8+ T cells and reduces chronic retroviral set points", Proc Natl Acad Sci USA., (20110124), vol. 108, no. 6, doi:10.1073/pnas.1015148108, pages 2420 - 5, XP055768620 |
| OPPOSITION | - SUGIYAMA D et al., "Anti-CCR4 mAb selectively depletes effector-type FoxP3+ CD 4+ regulatory T cells, evoking antitumor immune responses in humans", Proc Natl Acad Sci USA., (20131014), vol. 110, no. 44, doi:10.1073/pnas.1316796110, pages 17945 - 50, XP055284822 |
| OPPOSITION | - ISLAM et al., "Identification of human CCR8 as a 2013 CCL18 receptor", J. Exp. Med., (20130000), vol. 210, no. 10, doi:10.1084/jem.20130240, pages 1889 - 1898, XP055768625 |
| OPPOSITION | - Islam et al., "Identification of human CCR8 as a CCL18 receptor", Journal of Experimental Medicine, US , (20130923), vol. 210, no. 10, doi:10.1084/jem.20130240, ISSN 0022-1007, pages 1889 - 1898, XP055768625 |
| OPPOSITION | - SIMPSON TR et al., "Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma", J Exp Med., (20130729), vol. 210, no. 9, doi:10.1084/jem.20130579, pages 1695 - 710, XP055320296 |
| OPPOSITION | - Simpson Tyler R et al, "Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma", Journal of Experimental Medicine, Rockefeller University Press, US, US , (20130826), vol. 210, no. 9, doi:10.1084/jem.20130579, ISSN 0022-1007, pages 1695 - 1710, XP009176006 |
| OPPOSITION | - BOS et al., "Transient regulatory T cell ablation 2013 deters oncogene -driven breast cancer and enhances radiotherapy", J. Exp. Med., (20130000), vol. 210, no. 11, doi:10.1084/jem.20130762, pages 2435 - 2446, XP055768618 |
| OPPOSITION | - Bos et al., "Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy", Journal of Experimental Medicine, US , (20131021), vol. 210, no. 11, doi:10.1084/jem.20130762, ISSN 0022-1007, pages 2435 - 2446, XP055768618 |
| OPPOSITION | - BOS PD et al., "Transient regulatory T cell ablation deters oncogene -driven breast cancer and enhances radiotherapy", J Exp Med., (20131014), vol. 210, no. 11, doi:10.1084/jem.20130762, pages 2435 - 66, XP055768618 |
| OPPOSITION | - Paula D Bos; George Plitas; Dipayan Rudra; Sue Y Lee; Alexander Y Rudensky, "Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy", Journal of Experimental Medicine, (20130000), vol. 210, no. 11, pages 2435 - 2466, XP055768618 |
| OPPOSITION | - ZAHAVI et al., "Enhancing antibody-dependent cell -mediated cytotoxicity: a strategy for improving antibody-based immunotherapy", Antibody Therapeutics, (20180724), vol. 1, no. 1, pages 7 - 12, XP055836005 |
| OPPOSITION | - J. M. Kim, D. S. Chen, "Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)", Annals of Oncology, Kluwer Dordrecht, NL, NL , (20160801), vol. 27, no. 8, doi:10.1093/annonc/mdw217, ISSN 0923-7534, pages 1492 - 1504, XP055390469 |
| OPPOSITION | - KIM JM et al., "Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure", Ann Oncol., (20160520), vol. 27, no. 8, doi:10.1093/annonc/mdw217, pages 1492 - 504, XP055390469 |
| OPPOSITION | - YAMAMOTO N et al., "Anti-CC-chemokine receptor 4 (CCR4) antibody mogamulizumab (Moga) and nivolumab (Nivo) combination phase I study in patients with advanced or metastatic solid tumors", Annals of Oncology, (20170901), vol. 28, no. Suppl 5, page v611, XP055871962 |
| OPPOSITION | - TAKEUCHI et al., "Roles of regulatory T cells in cancer immunity", International Immunolgy, (20160000), vol. 28, no. 8, doi:10.1093/intimm/dxw025, pages 401 - 409, XP055396222 |
| OPPOSITION | - Takeuchi et al., "Roles of regulatory T cells in cancer immunity", International Immunology, GB , (20160822), vol. 28, no. 8, doi:10.1093/intimm/dxw025, ISSN 0953-8178, pages 401 - 409, XP055396222 |
| OPPOSITION | - TAKEUCHI Y et al., "Roles of regulatory T cells in cancer immunity", Int Immunol, (20160509), vol. 28, no. 8, doi:10.1093/intimm/dxw025, pages 401 - 9, XP055396222 |
| OPPOSITION | - Yoshiko Takeuchi; Hiroyoshi Nishikawa, "Roles of regulatory T cells in cancer immunity", International Immunology, (20160000), vol. 28, no. 8, pages 401 - 409, XP055396222 |
| OPPOSITION | - Yoshiko Takeuchi, Hiroyoshi Nishikawa, "Roles of regulatory T cells in cancer immunity", International Immunology, GB , (20160822), vol. 28, no. 8, doi:10.1093/intimm/dxw025, ISSN 0953-8178, pages 401 - 409, XP055396222 |
| OPPOSITION | - Yoshiko Takeuchi, Hiroyoshi Nishikawa, "Roles of regulatory T cells in cancer immunity", International Immunology, Oxford University Press, GB, GB , (20160822), vol. 28, no. 8, doi:10.1093/intimm/dxw025, ISSN 0953-8178, pages 401 - 409, XP055396222 |
| OPPOSITION | - Suzuki Susumu, Ishida Takashi, Yoshikawa Kazuhiro, Ueda Ryuzo, "Current status of immunotherapy", Jpn J Clin Oncol., (20160000), vol. 46, no. 3, pages 191 - 203, XP055866688 |
| OPPOSITION | - Griffith T. S., Et Al, "Inhibition of Murine Prostate Tumor Growth and Activation of Immunoregulatory Cells With Recombinant Canarypox Viruses", JOURNAL OF THE NATIONAL CANCER INSTITUTE, Oxford University Press, GB, GB , (20010704), vol. 93, no. 13, doi:10.1093/jnci/93.13.998, ISSN 0027-8874, pages 998 - 1007, XP055878787 |
| OPPOSITION | - Koji Kurose, Yoshihiro Ohue, Eiichi Sato, Akira Yamauchi, Shingo Eikawa, Midori Isobe, Yumi Nishio, Akiko Uenaka, Mikio Oka, Eiichi Nakayama, "Increase in Activated Treg in TIL in Lung Cancer and In Vitro Depletion of Treg by ADCC Using an Antihuman CCR4 mAb (KM2760)", Journal of Thoracic Oncology, US , (20150101), vol. 10, no. 1, doi:10.1097/JTO.0000000000000364, ISSN 1556-0864, pages 74 - 83, XP055284973 |
| OPPOSITION | - Arian D J Laurence, "Location, movement and survival: the role of chemokines in haematopoiesis and malignancy", Br J Haematol, (20050000), vol. 132, no. 3, pages 255 - 267, XP071121207 |
| OPPOSITION | - K. Mutalithas et al, "Expression of CCR8 is increased in asthma", CLIN EXP ALLERGY, (20100801), vol. 40, no. 8, doi:10.1111/j.1365-2222.2010.03504.x, pages 1175 - 1185, XP055739771 |
| OPPOSITION | - SIMONE DE HAIJ et al., "In vivo Cytotoxicity of Type I CD 20 Antibodies Critically Depends on Fc Receptor ITAM Signaling", Cancer Res, (20100415), vol. 70, no. 8, pages 3209 - 3217, XP055873637 |
| OPPOSITION | - KLAGES et al., "Selective Depletion of Foxp3+ Regulatory T Cells Improves Effective Therapeutic Vaccination against Established Melanoma", Cancer Res., (20101005), vol. 70, no. 20, doi:10.1158/0008-5472.CAN-10-1736, page 7788, XP055045950 |
| OPPOSITION | - KLAGES et al., "Selective Depletion of Foxp3+ Regulatory T Cells Improves Effective Therapeutic Vaccination against Established Melanoma", Cancer research, (20101000), vol. 70, no. 20, doi:10.1158/0008-5472.CAN-10-1736, pages 7788 - 7799, XP055045950 |
| OPPOSITION | - KLAGES K et al., "Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma", Cancer Res., (20101005), vol. 70, no. 20, doi:10.1158/0008-5472.CAN-10-1736, pages 7788 - 99, XP055045950 |
| OPPOSITION | - Teng Michele W.L., Ngiow Shin Foong, Ribas Antoni, Smyth Mark J., "Classifying Cancers Based on T-cell Infiltration and PD-L1", Cancer research, American Association for Cancer Research, US, US, (20150601), vol. 75, no. 11, doi:10.1158/0008-5472.CAN-15-0255, ISSN 0008-5472, pages 2139 - 2145, XP055854677 |
| OPPOSITION | - Daniel O. Villarreal, Andrew L'huillier, Susan Armington, Cristina Mottershead, Elena V. Filippova, Brandon D. Coder, Robert G. Petit, Michael F. Princiotta, "Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer", Cancer research, US , (20180915), vol. 78, no. 18, doi:10.1158/0008-5472.CAN-18-1119, ISSN 0008-5472, pages 5340 - 5348, XP055631142 |
| OPPOSITION | - Campbell Joseph R., Mcdonald Bryan R., Mesko Paul B., Siemers Nathan O., Singh Priti B., Selby Mark, Sproul Tim W., Korman Alan J., Vlach Logan M., Houser Jeff, Sambanthamoorthy Sharmila, Lu Kai, Hatcher Sandra V., Lohre Jack, Jain Renu, Lan Ruth Y., "Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models", Cancer Research, (20210000), vol. 81, no. 11, pages 2983 - 2994, XP055866698 |
| OPPOSITION | - IIDA et al., "Nonfucosylated Therapeutic IgG1Antibody Can Evade the Inhibitory Effect of Serum Immunoglobulin G on Antibody-Dependent Cellular Cytotoxicity through its High Binding to FcyRllla", Clinical Cancer Research, (20060501), vol. 12, no. 9, doi:10.1158/1078-0432.CCR-05-2619, pages 2879 - 2887, XP002432763 |
| OPPOSITION | - LIDA S et al., "Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRllla", Clin Cancer Res., (20060501), vol. 12, no. 9, doi:10.1158/1078-0432.CCR-05-2619, pages 2879 - 87, XP002432763 |
| OPPOSITION | - Ishii Toshihiko, Et Al, "Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma", Clinical Cancer Research, Association for Cancer Research, US, US, (20100301), vol. 16, no. 5, doi:10.1158/1078-0432.CCR-09-2697, ISSN 1078-0432, pages 1520 - 1531, XP055878572 |
| OPPOSITION | - ERUSLANOV E et al., "Expansion of CCR8(+) inflammatory myeloid cells in cancer patients with urothelial and renal carcinoma s", Clin Cancer Res., (20130130), vol. 19, no. 7, doi:10.1158/1078-0432.CCR-12-2091, pages 1670 - 80, XP055739724 |
| OPPOSITION | - ERUSLANOV et al., "Expansion of CCR8(+) inflammatory 2013 myeloid cells in cancer patients with urothelial and renal carcinomas", Clin Cancer Res, (20130130), vol. 19, no. 7, doi:10.1158/1078-0432.CCR-12-2091, pages 1670 - 80, XP055739724 |
| OPPOSITION | - ERUSLANOV et al., "Expansion of CCR8+ Inflammatory Myeloid Cells in Cancer Patients with Urothelial and Renal Carcinomas", Clin. Cancer Res., (20130130), vol. 19, no. 7, doi:10.1158/1078-0432.CCR-12-2091, page 1670, XP055739724 |
| OPPOSITION | - Eruslanov et al., "Expansion of CCR8+ Inflammatory Myeloid Cells in Cancer Patients with Urothelial and Renal Carcinomas", Clin. Cancer Res., (20130401), vol. 19, no. 7, doi:10.1158/1078-0432.CCR-12-2091, pages 1670 - 1680, XP055739724 |
| OPPOSITION | - Eruslanov, et al, "Expansion of CCR8+ Inflammatory Myeloid Cells in Cancer Patients with Urothelial and Renal Carcinomas", Clin. Cancer Res., (20130401), vol. 19, no. 7, doi:10.1158/1078-0432.CCR-12-2091, pages 1670 - 1680, XP055739724 |
| OPPOSITION | - ERUSLANOV et al., "Expansion of CCR8+ Inflammatory Myeloid Cells in Cancer Patients with Urothelial and Renal Carcinomas", Clinical Cancer Research, (20130130), vol. 19, no. 7, doi:10.1158/1078-0432.CCR-12-2091, pages 1670 - 1680, XP055739724 |
| OPPOSITION | - Eruslanov, Taryn et al, "Expansion of CCR8+ Inflammatory Myeloid Cells in Cancer Patients with Urothelial and Renal Carcinomas", Clin. Cancer Res., vol. 19, no. 7, doi:10.1158/1078-0432.CCR-12-2091, pages 1670 - 1680, XP055739724 |
| OPPOSITION | - Koji Kurose et al, "Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients", CLIN. CANCER RESEARCH, (20151001), vol. 21, no. 19, doi:10.1158/1078-0432.CCR-15-0357, pages 4327 - 4336, XP055739871 |
| OPPOSITION | - Koji Kurose; Yoshihiro Ohue; Hisashi Wada; Shinsuke Iida; Takashi Ishida; Takashi Kojima; Toshihiko Doi; Susumu Suzuki; Midori Isobe; Takeru Funakoshi; Kazuhiro Kakimi; Hiroyoshi Nishikawa; Heiichiro Udono; Mikio Oka; Ryuzo Ueda 1; Eiichi Nakayama, "Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients", Clin Cancer Res., (20150000), vol. 21, no. 19, pages 4327 - 4336, XP055739871 |
| OPPOSITION | - Koji Kurose, Yoshihiro Ohue , Hisashi Wada , Shinsuke Iida , Takashi Ishida , Takashi Kojima , Toshihiko Doi , Susumu Suzuki, Midori Isobe , Takeru Funakoshi , Kazuhiro Kakimi , Hiroyoshi Nishikawa , Heiichiro Udono , Mikio Oka , Ryuzo Ueda 1, Eiichi Nakayama, "Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients", CLIN. CANCER RESEARCH, (20151001), vol. 21, no. 19, doi:10.1158/1078-0432.CCR-15-0357, pages 4327 - 4336, XP055739871 |
| OPPOSITION | - Kurose et al., "Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients", CLIN. CANCER RESEARCH, (20151001), vol. 21, no. 19, doi:10.1158/1078-0432.CCR-15-0357, pages 4327 - 4336, XP055739871 |
| OPPOSITION | - KUROSE et al., "Phase la Study of FoxP3+ CD 4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients", Clin. Cancer Res., (20151001), vol. 21, no. 19, doi:10.1158/1078-0432.CCR-15-0357, page 4327, XP055739871 |
| OPPOSITION | - KUROSE K et al., "Phase la Study of FoxP3+ CD 4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients", Clin Cancer Res., (20151001), vol. 21, no. 19, doi:10.1158/1078-0432.CCR-15-0357, pages 4327 - 36, XP055739871 |
| OPPOSITION | - Fabien Dépis, Hu Changyun, Weaver Jessica, Mcgrath Lara, Klebanov Boris, Buggé Joshua, Umiker Ben, Fregeau Christine, Upadhyay Dhruvkumar, Singh Anirudh, Xu Chang-Ai, Spaulding Vikki, Priess Michelle, Wong Masie, Naheed Seema, Zhang Yan, Legendre Kristin, Stack Edward C, Mora Alessandro, Willer Margaret, Meetze Kristan, Gostissa Monica, Meehl Michael A, Shaffer Donald R, "Abstract 4532: Preclinical evaluation of JTX-1811, an antiCCR8 antibody with enhanced ADCC activity, for preferential depletion of tumor-infiltrating regulatory T cells", Cancer Res. Proceedings: AACR Annual Meeting, doi:10.1158/1538-7445.AM2020-4532Published, (20200427), Cancer Res. Proceedings: AACR Annual Meeting, URL: https://cancerres.aacrjournals.org/content/80/16_Supplement/4532, (20210126), XP055768627 |
| OPPOSITION | - G Plitas, C Konopacki, K Wu, B Paula, M Morrow, A Rudensky, "Abstract P4-04-11: Preferential expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target", Cancer research, American Association for Cancer Research, US, US , (20160215), vol. 76, no. 4 Supplement, doi:10.1158/1538-7445.SABCS15-P4-04-11, ISSN 0008-5472, pages P4 - P4-04-11, XP055396219 |
| OPPOSITION | - G Plitas, C Konopacki, K Wu, B Paula, M Morrow, A Rudensky, "Abstract P4-04-11: Preferential expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target", Cancer research, US , (20160215), vol. 76, no. 4 Supplement, doi:10.1158/1538-7445.SABCS15-P4-04-11, ISSN 0008-5472, pages P4 - P4-04-11, XP055396219 |
| OPPOSITION | - G Plitas et al, "Abstract P4-04-11: Preferential expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target", Cancer research, American Association for Cancer Research, US, US , (20160215), vol. 76, no. 4 Supplement, doi:10.1158/1538-7445.SABCS15-P4-04-11, ISSN 0008-5472, pages P4 - P4-04-11, XP055396219 |
| OPPOSITION | - PLITAS et al., "Abstract P 4-04 -11: Preferential 2016 expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target", Cancer Res., (20160000), vol. 76, no. 4 Supplement, doi:10.1158/1538-7445.SABCS15-P4-04-11, XP055396219 |
| OPPOSITION | - Plitas et al., "Abstract P4-04-11: Preferential expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target", Cancer research, US , (20160215), vol. 76, no. 4 Supplement, doi:10.1158/1538-7445.SABCS15-P4-04-11, ISSN 0008-5472, XP055396219 |
| OPPOSITION | - Plitas G; Konopacki C; Wu K; Paula B; Morrow M; Rudensky A, "Abstract P4-04-11: Preferential expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target", Cancer research, (20160000), vol. 76, no. 4, pages 4 - 04-11, XP055396219 |
| OPPOSITION | - KIM et al., "Immunopathogenesis and therapy of cutaneous T cell lymphoma", The Journal of Clinical Investigation, (20050000), vol. 115, pages 798 - 812, XP055271996 |
| OPPOSITION | - DANNULL et al., "Enhancement of vaccine- 2005 mediated antitumor immunity in cancer patients after depletion of regulatory T cells", J. Clin. Invest., (20050000), vol. 115, doi:10.1172/JCI25947, pages 3623 - 3633, XP002396935 |
| OPPOSITION | - DANNULL J et al., "Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells", J Clin Invest, (20051123), vol. 115, no. 12, doi:10.1172/JCI25947, pages 3623 - 33, XP002396935 |
| OPPOSITION | - DANNULL J, ET AL, "Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells", The Journal of Clinical Investigation, GB , (20051201), vol. 115, no. 12, doi:10.1172/JCI25947, ISSN 0021-9738, pages 3623 - 3633, XP002396935 |
| OPPOSITION | - Lieping Chen; Xue Han, "Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future", The Journal of Clinical Investigation, (20150000), vol. 125, no. 9, pages 3384 - 3391, XP055432081 |
| OPPOSITION | - ZELINSKYY et al., "The regulatory T- cell response 2009 during acute retroviral infection is locally defined and controls the magnitude and duration of the virus- specific cytotoxic T- cell", Blood, (20090000), vol. 114, no. 15, doi:10.1182/blood-2009-03-208736, pages 3199 - 3207, XP055768621 |
| OPPOSITION | - Zelinskyy et al., "The regulatory T- cell response during acute retroviral infection is locally defined and controls the magnitude and duration of the virus- specific cytotoxic T- cell response", Blood, US , (20091008), vol. 114, no. 15, doi:10.1182/blood-2009-03-208736, ISSN 0006-4971, pages 3199 - 3207, XP055768621 |
| OPPOSITION | - ZELINSKYY G et al., "The regulatory T- cell response during acute retroviral infection is locally defined and controls the magnitude and duration of the virus- specific cytotoxic T- cell response", Blood, (20091008), vol. 114, no. 15, doi:10.1182/blood-2009-03-208736, pages 3199 - 207, XP055768621 |
| OPPOSITION | - BRUHNS, PIERRE, "Properties of mouse and human IgG receptors and their contribution to disease models", Blood, (20120425), vol. 119, no. 24, doi:10.1182/blood-2012-01-380121, pages 5640 - 5649, XP055249198 |
| OPPOSITION | - HOWARD et al., "LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8", Blood J., (20000000), vol. 96, no. 3, doi:10.1182/blood.V96.3.840.015k32_840_845, pages 840 - 845, XP055768624 |
| OPPOSITION | - Howard et al., "LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8", Blood, US , (20000801), vol. 96, no. 3, doi:10.1182/blood.V96.3.840.015k32_840_845, ISSN 0006-4971, pages 840 - 845, XP055768624 |
| OPPOSITION | - RUCKES, T. et al., "T- cell leukemia cells by overexpression of the chemokine I- 309. Autocrine antiapoptotic stimulation of cultured adult", Blood, (20010000), vol. 98, doi:10.1182/blood.V98.4.1150, pages 1150 - 1159, XP002264850 |
| OPPOSITION | - S, KUNI-KAMOCHI R et al., "Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non- fucosylated therapeutic antibodies in human blood", BMC Cancer, (20090218), vol. 9, doi:10.1186/1471-2407-9-58, page 58, XP021049068 |
| OPPOSITION | - Heiyoun Jung et al, "Combination therapy of chemokine receptor inhibition plus PDL-1 blockade potentiates anti-tumor effects in a murine model of breast cancer", Journal for ImmunoTherapy of Cancer, BioMed Central Ltd, London, UK, London, UK , (20151104), vol. 3, no. 2, doi:10.1186/2051-1426-3-S2-P227, pages 1 - 1, XP021235255 |
| OPPOSITION | - ANGELOVA et al., "Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy", Genom Biol, (20150000), vol. 16, no. 1, doi:10.1186/s13059-015-0620-6, page 64, XP021220596 |
| OPPOSITION | - ANGELOVA et al., "Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherap y", Genome Biol, vol. 16, no. 1, doi:10.1186/s13059-015-0620-6, (20150331), page 64, XP021220596 |
| OPPOSITION | - FINOTELLO et al., "New strategies for 2017 cancer immunotherapy: targeting regulatory T cells", Genome Medicine, (20170000), vol. 9, doi:10.1186/s13073-017-0402-8, page 10, XP055396226 |
| OPPOSITION | - FINOTELLO et al., "New Strategies for cancer immunotherapy: targeting regulatory T cells", Genome Medicine, (20170000), vol. 9, doi:10.1186/s13073-017-0402-8, page 10, XP055396226 |
| OPPOSITION | - Francesca Finotello, Trajanoski Zlatko, "New strategies for cancer immunotherapy: targeting regulatory T cells", GENOME MEDICINE, (20170127), vol. 9, no. 1, doi:10.1186/s13073-017-0402-8, ISSN 1756-994X, XP055396226 |
| OPPOSITION | - Mordant Pierre, Et Al, "Bioluminescent Orthotopic Mouse Models of Human Localized Non-Small Cell Lung Cancer: Feasibility and Identification of Circulating Tumour Cells", PLoS ONE, Public Library of Science, US, US , (20110101), vol. 6, no. 10, doi:10.1371/journal.pone.0026073, ISSN 1932-6203, pages 1 - 9, XP055878620 |
| OPPOSITION | - Fu Qiang, Et Al, "Positive intratumoral chemokine (C-C motif) receptor 8 expression predicts high recurrence risk of post-operation clear-cell renal cell carcinoma patients", Oncotarget, (20160216), vol. 7, no. 7, doi:10.18632/oncotarget.6761, pages 8413 - 8421, XP055878666 |
| OPPOSITION | - RAJASEKARAN et al., "Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment", ImmunoTargets and Therapy, (20150515), vol. 4, doi:10.2147/ITT.S61292, pages 91 - 100, XP055382587 |
| OPPOSITION | - Ursula J. E. Seidel, Patrick Schlegel and Peter Lang, "Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies", Frontiers in Immunology, Lausanne, CH , (20130327), vol. 4, no. 76, doi:10.3389/FIMMU.2013.00076, ISSN 1664-3224, pages 1 - 8, XP002714182 |
| OPPOSITION | - Robertson Faith C., Et Al, "NKT Cell Networks in the Regulation of Tumor Immunity", Frontiers in Immunology, doi:10.3389/fimmu.2014.00543, (20141028), pages 1 - 12, Frontiers in Immunology, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211539/pdf/fimmu-05-00543.pdf, (20220113), XP055878672 |
| OPPOSITION | - VELA et al., "Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges", Frontiers in Immunology, (20150130), vol. 6, doi:10.3389/fimmu.2015.00012, page 1, XP055455872 |
| OPPOSITION | - VELA et al., "Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges", Frontiers in Immunology, (20150130), vol. 6, doi:10.3389/fimmu.2015.00012, pages 1 - 15, XP055455872 |
| OPPOSITION | - VELA M et al., "Chemokine receptor- specific antibodies in cancer immunotherapy: achievements and challenges", Front Immunol, (20150130), vol. 6, doi:10.3389/fimmu.2015.00012, page 12, XP055455872 |
| OPPOSITION | - KIM et al., "Cutting edge: depletion of Foxp3p 2009 cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice", J. Immunol., (20090000), vol. 183, doi:10.4049/jimmunol.0804308, pages 7631 - 7634, XP055768619 |
| OPPOSITION | - D. B. Hoelzinger et al, "Blockade of CCL1 Inhibits T Regulatory Cell Suppressive Function Enhancing Tumor Immunity without Affecting T Effector Responses", The Journal of Immunology, Williams & Wilkins Co., US, US , (20100615), vol. 184, no. 12, doi:10.4049/jimmunol.0904084, ISSN 0022-1767, pages 6833 - 6842, XP055306968 |
| OPPOSITION | - D. B. Hoelzinger, S. E. Smith, N. Mirza, A. L. Dominguez, S. Z. Manrique, J. Lustgarten, "Blockade of CCL1 Inhibits T Regulatory Cell Suppressive Function Enhancing Tumor Immunity without Affecting T Effector Responses", The Journal of Immunology, US , (20100615), vol. 184, no. 12, doi:10.4049/jimmunol.0904084, ISSN 0022-1767, pages 6833 - 6842, XP055306968 |
| OPPOSITION | - HOELZINGER DB et al., "Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses", J Immunol., (20100507), vol. 184, no. 12, doi:10.4049/jimmunol.0904084, pages 6833 - 42, XP055306968 |
| OPPOSITION | - Hoelzinger D B; Smith S E; Mirza N; Dominguez A L; Manrique S Z; Lustgarten J, "Blockade of CCL1 Inhibits T Regulatory Cell Suppressive Function Enhancing Tumor Immunity without Affecting T Effector Responses", The Journal of Immunology, (20100000), vol. 184, no. 12, pages 6833 - 6842, XP055306968 |
| OPPOSITION | - HOELZINGER et al., "Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses", J. Immunol., (20100000), vol. 184, doi:10.4049/jimmunol.0904084, pages 6833 - 6842, XP055306968 |
| OPPOSITION | - HOELZINGER et al., "Blockade of CCL1 Inhibits T Regulatory Cell Suppressive Function Enhancing Tumor Immunity without Affecting T Effector Responses", J. Immunol., (20100615), vol. 184, no. 12, doi:10.4049/jimmunol.0904084, page 6833, XP055306968 |
| OPPOSITION | - Hoelzinger et al., "Blockade of CCL1 Inhibits T Regulatory Cell Suppressive Function Enhancing Tumor Immunity without Affecting T Effector Responses", The Journal of Immunology, US , (20100615), vol. 184, no. 12, doi:10.4049/jimmunol.0904084, ISSN 0022-1767, pages 6833 - 6842, XP055306968 |
| OPPOSITION | - Dhodapkar Madhav V., Kumar Vipin, "Type II NKT Cells and Their Emerging Role in Health and Disease", The Journal of Immunology, Williams & Wilkins Co., US, US , (20170201), vol. 198, no. 3, doi:10.4049/jimmunol.1601399, ISSN 0022-1767, pages 1015 - 1021, XP055878675 |
| OPPOSITION | - Aaron Nelson, "Antibody fragments", mAbs 2:1, 77-83; January/February 2010, doi:10.4161/mabs.2.1.10786, (20100101), pages 77 - 83, mAbs 2:1, 77-83; January/February 2010, URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828581/pdf/mabs0201_0077.pdf, (20130125), XP055051226 |
| SEARCH | - TAN SHUGUANG ET AL, "Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies", PROTEIN & CELL, SPRINGER ASIA, BEIJING, CN, vol. 7, no. 12, doi:10.1007/S13238-016-0337-7, ISSN 1674-800X, (20161104), pages 866 - 877, (20161104), XP036124172 [Y] 6-20 * whole document, especially the Abstract; Table 1 * |
| SEARCH | - PLITAS GEORGE ET AL, "Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer", IMMUNITY, CELL PRESS, US, (20161115), vol. 45, no. 5, doi:10.1016/J.IMMUNI.2016.10.032, ISSN 1074-7613, pages 1122 - 1134, XP029809259 [I] 1,3-5,11-20 * whole document, especially the Abstract * [Y] 6-20 [A] 2 |
| SEARCH | - G PLITAS ET AL, "Abstract P4-04-11: Preferential expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target", CANCER RESEARCH, US, (20160215), vol. 76, no. 4 Supplement, doi:10.1158/1538-7445.SABCS15-P4-04-11, ISSN 0008-5472, pages P4-04-11 - P4-04-11, XP055396219 [I] 1,3-5,11-14 * whole document, especially the "Conclusions" * [Y] 6-20 [A] 2 |
